CBL-514 keeps showing up in conversations about fat loss, often next to GLP-1 drugs and peptides. It is a genuinely interesting drug candidate, but it is easy to misunderstand. Here is what it is, how it is meant to work, what the trials have shown so far and where it stands today.
What CBL-514 is (and what it isn't)
CBL-514 is an injectable drug candidate developed by Caliway Biopharmaceuticals, a company based in Taiwan. It is designed to reduce fat in one specific area of the body, such as the abdomen, without surgery.
The first thing to know: CBL-514 is not a peptide. Caliway describes it as a first-in-class small molecule, meaning a compact chemical drug rather than a chain of amino acids like MOTS-c or BPC-157. It is often grouped with peptides online because it is discussed in the same weight-loss and body-composition circles, but it is a different kind of compound.
It is also not a weight-loss drug in the way semaglutide or tirzepatide are. Those drugs act on appetite and metabolism throughout the body. CBL-514 is injected into a target area and is meant to work right where it is placed.
How it is designed to work
Caliway says CBL-514 selectively triggers apoptosis in fat cells at the injection site. Apoptosis is a controlled, orderly form of cell death that the body uses all the time to clear old or unneeded cells. Fewer fat cells in an area should mean less fat there, and the company states that surrounding tissue is spared. In its early announcements Caliway also described CBL-514 as a lipolysis injectable, meaning it releases stored fat, and pointed to laboratory markers of apoptosis such as caspase-3 activity.
That idea sets it apart from the best-known approved fat-reducing injection in the United States. Kybella (deoxycholic acid), approved in 2015 for fat under the chin, is a cytolytic drug: it breaks open fat cell membranes. Caliway's pitch is that a controlled, apoptosis-based approach could treat larger areas, such as the abdomen, which Kybella is not approved for.
What the research shows
Phase 2 studies for abdominal fat
- CBL-0204 (phase 2b): 107 adults with moderate to severe belly fat were randomized to CBL-514 or placebo, with up to four treatment sessions three weeks apart. Twelve weeks after the last session, 76.7% of the CBL-514 group improved by at least one grade on a clinician-rated abdominal fat scale, compared with 18.9% on placebo. About a third (32%) improved by two grades or more, versus none on placebo. On MRI, half of the CBL-514 group had lost at least 150 mL of fat under the skin four weeks after treatment, compared with none on placebo.
- CBL-0205 (phase 2b): 21.2% of people on CBL-514 reached a two-grade improvement on combined clinician and patient ratings, versus 0% on placebo, and 63.6% reached at least a one-grade improvement, versus 10.8%.
- Safety so far: The most common side effects reported were mild to moderate injection-site reactions.
Visceral fat: an early signal
At the European Association for the Study of Diabetes meeting in 2026, researchers presented an MRI analysis of 46 people from those two phase 2 studies. Visceral fat, the deeper fat around the organs, fell about 11% with CBL-514 four weeks after treatment while it rose about 5% with placebo. Independent experts urged caution: it was a small, after-the-fact subgroup analysis with no full paper, the placebo group gained fat (which makes the difference look larger), and it does not show that the drug improves health.
Other uses being studied
- Dercum's disease, a rare condition with painful fatty lumps called lipomas. In a 12-person open-label phase 2 study, the higher dose shrank lipomas by about half on average and lowered pain scores. A larger phase 2b study has since finished collecting data.
- Cellulite, which Caliway has listed as another target.
- Pairing with GLP-1 drugs. In rats, adding CBL-514 to tirzepatide reduced weight regain after treatment stopped. The FDA cleared a 120-person phase 2 trial in August 2026 to test that combination in people.
An honest look at the evidence
The phase 2 results are encouraging, and the trials were randomized and placebo-controlled. But most of the data so far come from company announcements and conference presentations rather than full peer-reviewed papers, and the studies were short. The phase 3 trials are where the real test happens.
Where it stands now
- Status: Investigational. CBL-514 is not approved by the FDA or any other regulator, for any use.
- SUPREME-01: The first global phase 3 trial, cleared by the FDA in July 2025, is enrolling about 320 people across the United States and Canada. It is randomized, double-blind and placebo-controlled, and success means at least a two-grade improvement on both clinician and patient fat ratings. Caliway announced its first participant dosed in September 2026.
- SUPREME-02: A second phase 3 trial has regulatory clearance in the United States, Canada and Australia. In August 2026 Caliway said enrollment would start on schedule.
- Timeline: No phase 3 results have been reported. Approval, if it comes, depends on those trials.
For the library summary, see our CBL-514 brief. If you are comparing it with metabolic peptides, our MOTS-c brief and tirzepatide brief cover how those work.
Key references
- Caliway Biopharmaceuticals. Results from CBL-0204, a CBL-514 phase 2b study for reducing abdominal subcutaneous fat. Company announcement, December 11, 2024. ClinicalTrials.gov NCT05736107.
- Caliway Biopharmaceuticals. Highlights from the 2026 second-half investor conference, August 31, 2026.
- Caliway Biopharmaceuticals. First patient dosed in the global phase 3 SUPREME-01 trial, September 23, 2026.
- Ling Y, et al. Visceral fat analysis of the CBL-0204 and CBL-0205 studies. Abstract presented at EASD 2026; reported by HCPLive, October 7, 2026.
- Caliway Biopharmaceuticals. CBL-514 phase 2 topline results in Dercum's disease. Company announcement, September 13, 2023.
- Clinical Trials Arena. FDA clears Caliway's trial of CBL-514 for localised fat reduction, July 29, 2025.
This post is educational. CBL-514 is an investigational drug; nothing here is dosing guidance or a recommendation to use it.